- Home
- TNGX vs NCZ Comparison
TNGX vs NCZ Comparison
Compare TNGX & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- NCZ
- Stock Information
- Founded
- TNGX 2014
- NCZ 2003
- Country
- TNGX United States
- NCZ United States
- Employees
- TNGX N/A
- NCZ N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- NCZ Finance Companies
- Sector
- TNGX Health Care
- NCZ Finance
- Exchange
- TNGX Nasdaq
- NCZ Nasdaq
- Market Cap
- TNGX 351.2M
- NCZ 228.3M
- IPO Year
- TNGX N/A
- NCZ N/A
- Fundamental
- Price
- TNGX $6.01
- NCZ $12.99
- Analyst Decision
- TNGX Strong Buy
- NCZ
- Analyst Count
- TNGX 6
- NCZ 0
- Target Price
- TNGX $12.20
- NCZ N/A
- AVG Volume (30 Days)
- TNGX 2.7M
- NCZ 533.0K
- Earning Date
- TNGX 08-06-2025
- NCZ 01-01-0001
- Dividend Yield
- TNGX N/A
- NCZ 12.16%
- EPS Growth
- TNGX N/A
- NCZ N/A
- EPS
- TNGX N/A
- NCZ N/A
- Revenue
- TNGX $40,990,000.00
- NCZ N/A
- Revenue This Year
- TNGX N/A
- NCZ N/A
- Revenue Next Year
- TNGX N/A
- NCZ N/A
- P/E Ratio
- TNGX N/A
- NCZ N/A
- Revenue Growth
- TNGX 10.09
- NCZ N/A
- 52 Week Low
- TNGX $1.03
- NCZ $2.50
- 52 Week High
- TNGX $12.02
- NCZ $3.15
- Technical
- Relative Strength Index (RSI)
- TNGX 76.36
- NCZ 75.05
- Support Level
- TNGX $5.34
- NCZ $12.78
- Resistance Level
- TNGX $6.40
- NCZ $12.95
- Average True Range (ATR)
- TNGX 0.50
- NCZ 0.14
- MACD
- TNGX -0.02
- NCZ 0.02
- Stochastic Oscillator
- TNGX 84.08
- NCZ 97.56
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.